Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes

• Published in: Stem cell research Vol. 4; no. 2; p. 107
• Main Authors: Braam, Stefan R, Tertoolen, Leon, van de Stolpe, Anja, Meyer, Thomas, Passier, Robert, Mummery, Christine L
• Format: Journal Article
• Language: English
• Published: England 01-03-2010
• Subjects: Animals; Cell Line; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Electrophysiology; Embryonic Stem Cells - cytology; Humans; Lidocaine - toxicity; Long QT Syndrome - chemically induced; Mice; Myocytes, Cardiac - cytology; Myocytes, Cardiac - drug effects; Patch-Clamp Techniques; Quinidine - toxicity; Sotalol - toxicity
• ISSN: 1876-7753
• DOI: 10.1016/j.scr.2009.11.004

Recent withdrawals of prescription drugs from clinical use because of unexpected side effects on the heart have highlighted the need for more reliable cardiac safety pharmacology assays. Block of the human Ether-a-go go Related Gene (hERG) ion channel in particular is associated with life-threatening arrhythmias, such as Torsade de Pointes (TdP). Here we investigated human cardiomyocytes derived from pluripotent (embryonic) stem cells (hESC) as a renewable, scalable, and reproducible system on which to base cardiac safety pharmacology assays. Analyses of extracellular field potentials in hESC-derived cardiomyocytes (hESC-CM) and generation of derivative field potential duration (FPD) values showed dose-dependent responses for 12 cardiac and noncardiac drugs. Serum levels in patients of drugs with known effects on QT interval overlapped with prolonged FPD values derived from hESC-CM, as predicted. We thus propose hESC-CM FPD prolongation as a safety criterion for preclinical evaluation of new drugs in development. This is the first study in which dose responses of such a wide range of compounds on hESC-CM have been generated and shown to be predictive of clinical effects. We propose that assays based on hESC-CM could complement or potentially replace some of the preclinical cardiac toxicity screening tests currently used for lead optimization and further development of new drugs.